Dr. Ernst Christian Friedrich Schering begins developing and selling pharmaceutical products in Berlin. Three years later, the company opens its first production facility.
Ernst Schering, centre, with the board of directors of Schering AG circa 1885. The company was incorporated in 1871.
Leaving Darmstadt, Germany, George Merck arrives in New York and establishes Merck & Co., Inc.
The MSD Manual begins publication, providing professionals with the best available medical knowledge of the day.
The founder’s son, George W. Merck, launches major new research laboratories in Rahway, New Jersey, soon leading to breakthroughs in vitamins, antibiotics, and anesthetics.
MSD’s penicillin “G” (Penalev) is used in the first successful treatment of blood infection with penicillin in the U.S. Ramping up production for the war earns the company the Army-Navy “E” Award for excellence in manufacturing.
In collaboration with MSD, Dr. Selman Waksman of Rutgers University produces streptomycin, the world’s first cure for tuberculosis. The company waives the patent rights.
The merger with Sharp & Dohme brings to the company important new expertise in biologicals and vaccine research, and global distribution.
Dr. E.B. Hershberg, standing top right, leads the team that synthesizes prednisone and prednisolone. These “Meti” drugs fuel Schering’s second big wave of growth in the mid-1950s.
A company foundation is created to manage the corporation’s growing philanthropic endeavours.
Diuril (chlorothiazide) is launched for congestive heart failure and high blood pressure – the first major product in the company’s new cardiovascular line.
In 1971 M-M-R II (measles, mumps, and rubella virus vaccine, live) is launched in an innovative combined form.
Considered the most complex drug synthesis process of the time, the broad-spectrum antibiotic Primaxin is launched.
Recombivax HB (hepatitis B vaccine, recombinant) is launched – the first genetically engineered vaccine approved for humans, and the first to prevent cancer.
Mectizan (ivermectin) is developed for river blindness and distributed free to all who need it. Since then, the company has donated 2.5 million tablets (estimated value of $3.75 billion).
Following a decade of intensive research, Crixivan (indinavir sulfate) is approved for treating HIV in just 45 days – one of the fastest FDA reviews to date.
CEO and President Dick Clark launches the ”Plan to Win” to address challenges and transform the company into a leader in the pharmaceutical industry.
In 2006 Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] becomes the first vaccine to prevent cervical cancer (the second-leading cause of cancer deaths among women worldwide).
Kenneth C. Frazier, the company’s chairman, president and chief executive officer, leads the company into a new era of global healthcare.
The company launches the 10-year MSD for Mothers initiative, a global effort to bring the issue of maternal mortality to the forefront of global consciousness.
The Mectizan Donation Program celebrates its 25th anniversary.
MSD’s innovative treatment for advanced melanoma was the first drug to be made available through the government’s Early Access to Medicines Scheme (EAMS) - helping patients benefit from promising, innovative treatments in advance of a European licence being granted.
2016 marked our 125th anniversary as a global healthcare leader.
This is an exciting time for our company and the world. Today, we are at the forefront of inventing tools for the fight against some of the world's most urgent global health challenges. This includes more than 30 different cancers, hepatitis C, Alzheimer’s disease, Ebola, antibiotic-resistant “superbugs,” cardio-metabolic diseases, and many others.
Since our inception in 1891, MSD has pushed the boundaries of science with the hope and expectation that advancing scientific knowledge will lead to major advances in health. MSD has changed the world repeatedly through our history – from the development of the first vaccines for measles and mumps and the first vaccine for HPV, an infection that causes cervical and other cancers, to the development of ground-breaking medicines for heart disease, osteoporosis, diabetes, tuberculosis, HIV and melanoma, just to name a few.